Major insurer partners with private equity firm for care coordination

Insurance giant Elevance Health entered into an agreement with private equity firm Clayton, Dubilier & Rice (CD&R), specifically its healthcare companies Apree Health and Millennium Physician Group (MPG).

In an announcement, Elevance said the move aims to expand patient access to primary care services for its Carelon Health patients. Through the development of a new managed care program, the companies will seek to more efficiently address patient care needs, mental as well as physical. This “whole health approach” will be supported by care coordination, health coaching and support, as well as data analytics, effectively combining the offerings of the companies.

The new care plan is expected to impact 1 million patients from Carelon's 30 clinics and beyond, as patients from MPG and Apree join, Elevance said. 

“We know that when primary care providers are resourced and empowered, they guide consumers through some of life’s most vulnerable moments, while helping people to take control of their own health,” Bryony Winn, president of health solutions at Elevance says in the announcement. “By bringing a new model of advanced primary care to markets across the country, our partnership with CD&R will create a win-win for consumers and care providers alike.”

The specific terms of the financial agreement were not disclosed. However, Elevance aid it will be investing in the CD&R companies through a combination of cash and equity from Carleon.

This week, Elevance’s stock rose 4.7% when the company reported a higher-than-expected “operating gain” of $2.3 billion.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.